Back
Livzon Pharma Psoriasis Drug Gains China's Priority Review
Back
Stock News
Themes
Livzon Pharma Psoriasis Drug Gains China's Priority Review
Livzon Pharma Psoriasis Drug Gains China's Priority Review
Edgen Stock
·
Jan 07 2026, 15:39
Share to
Share to
Copy link
LIVZON PHARMA
+3.73%
source:
[1] Livzon Pharma (01513.HK)'s Laikangqita Monoclonal Antibody Injection Granted Priority Review Status
Recommend
Agriculture ETFs Break Out on Fertilizer Supply Fears
Mar 06 2026, 16:17
Tango Therapeutics Stock Hits Record High on Erasca Cancer Trial Deal
Mar 06 2026, 16:02
Parker-Hannifin Stock Climbs 53% on Aerospace Demand
Mar 06 2026, 16:01
Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Themes
Crypto Comparison
Home Page
Resources
Tutorial
Gitbook
Team
Aura Insights
Market
US Market
HK Market
Crypto Market
Terms of Use
Privacy Policy
Sitemap
© 2026 Finture Development Limited. All rights reserved
Edgen Stock·Jan 07 2026, 15:39Edgen Stock·Jan 07 2026, 15:39
Edgen Stock·Jan 07 2026, 15:39